ConvaTec Group PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ConvaTec Group PLC
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.
- Drug Delivery
- Consumables, Central Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Hospitak, Inc.
- Maersk Medical
- Unomedical a/s
- Woodbury Holdings
- ConvaTec, Inc.